Registering Genomics and Imaging of Tumors
J
Jason Parker
Primary Investigator
Overview
This research is being done to see if genetic mutations inside brain tumors can be identified using pictures from MRI or PET scanners, instead of using needles or surgery. To conduct the study, we need to take pictures of the locations of tumor samples as they are removed during surgery. The samples then get studied for genetic mutations, and we look at the parts of the image the samples came from to see if they could have been predicted.
Description
Participants will be asked to complete a study visit before biopsy in which they will undergo an MRI and PET scan. During biopsy, researchers will take pictures of the tumor and take research samples of the tumor. Researchers will collect information from regularly scheduled follow-up visits after the biopsy.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Glioma
-
Age: Between 18 Years - 89 Years
-
Gender: All
Inclusion Criteria:
- Has radiologically-diagnosed or suspected WHO Grade II-IV glioma based on physician review or conformance with published WHO criteria as evaluated by the PI*
- Treatment-naïve for the above condition.
- Planning to undergo surgical resection and biopsy of their brain tumor.
- Has sufficient tissue so that the study team is able to acquire at least 2 biopsy samples during resection.
- Able to read and write in English.
- Able to lay supine for up to 80 minutes.
- Able to hold still during MRI procedures.
- Participant or their LAR has signed the consent form for participation in the study.
Exclusion Criteria:
- Subject has conditions that would preclude the completion of an MRI such as claustrophobia, pacemaker, metal objects in the body, and/or pregnancy.
- Subject has serious unstable medical or mental illness.
- Subject has insufficient tissue to acquire at least two biopsy samples during resection.
- Subject has a medical contraindication to any element of the study procedures.
- Subject or their LAR has not read and signed the informed consent form, or does not understand its contents.
- Subject is pregnant.
- Subject is at high risk for NSF (eGFR<60 or serum creatine >1.3) and cannot follow the weight-based dosing protocol for Gadavist.
Updated on
29 Apr 2024.
Study ID: 11163, RADY-IIR-REGIT
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
